BioSpace News Archive

Bayshore Pharmaceuticals, LLC is pleased to introduce three new FDA-approved products to their expanding portfolio.

AcelRx Pharmaceuticals, Inc. today announced it has entered into an agreement with two life sciences-focused investment funds that are existing and new stockholders in AcelRx, for the sale of 17,500,000 shares of common stock and warrants exercisable for an aggregate of 17,500,000 shares of common stock.

Osmotica Pharmaceuticals plc announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Jefferies London Virtual Healthcare Conference 2021 as follows: Date: Thursday, November 18, 2021

InfuSystem Holdings, Inc. today reported financial results for the third quarter ended September 30, 2021.

Protalix BioTherapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a financial and business update on recent corporate, clinical and regulatory developments.

Asensus Surgical, Inc. today announced the Franklin Medical Center in Winnsboro, Louisiana has entered into an agreement to lease and utilize a Senhance® Surgical System.

Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic T Cell priming vaccines today announces that it has received the necessary regulatory approvals to initiate a Phase I clinical trial to evaluate the safety and tolerability of its vaccine candidate for SARS-CoV-2, the virus which causes COVID-19.

Aravive, Inc., a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 – December 2, 2021.

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA), today announced that Kirk Huntsman, Chief Executive Officer, Brad Amman, Chief Financial Officer and Ed Loew, Investor Relations Officer, will be presenting at the Q4 Virtual Investor Summit.

Zynerba Pharmaceuticals , Inc. today reported financial results for the third quarter ended September 30, 2021, and provided an overview of recent operational highlights and a pipeline update.